Priority Date: 28.02.12 (US 201261603970P)

COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION

  • Application ID: EP13755285
  • Status: GRANT OF PATENT INTENDED

Attorneys

Employment test 51 - 200 employees
Company dna boult wade tennant ltd
no operation time available
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing
Employment test 51 - 200 employees
Company dna matias erny reichl hoffmann
operating since 2009
Headquarter in Munich
active in Legal Services and IP Consulting

Specialization

This patent has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) is specialized in A61. Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 28.02.2012 - Priority Date (US 201261603970P)
  • 06.09.2013 - Publication A1 (WO2013128381)
  • 07.01.2015 - Publication A1 (EP2819698)

IPC Classification